Breaking News:
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus“ in diese Kupferaktie investierte
Anzeige
INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion
14,79 EUR
-1,12 %-0,17
7. Nov, 17:30:16 Uhr,
Quotrix Düsseldorf
Kommentare 428
S
Steffen2012,
01.03.2022 16:25 Uhr
0
Mhhh wenn ich jetzt alles richtig verstanden habe, muss Intellia jetzt aber einen Lizenzvertrag mit dem Patentinhaber abschließen oder? Ansonsten können sie ja nicht weiter machen. Oder ?
Summer.76,
28.02.2022 22:36 Uhr
0
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
https://www.globenewswire.com/news-release/2022/02/28/2393640/0/en/Intellia-and-Regeneron-Announce-Updated-Phase-1-Data-Demonstrating-a-Single-Dose-of-NTLA-2001-an-Investigational-CRISPR-Therapy-for-Transthyretin-ATTR-Amyloidosis-Resulted-in-Rapid.html
• Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels
• Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months
• NTLA-2001 was generally well tolerated at all dose levels
• On track to initiate polyneuropathy dose-expansion cohort (Part 2) in Q1 2022
Summer.76,
24.02.2022 16:51 Uhr
0
https://www.globenewswire.com/news-release/2022/02/24/2391296/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Highlights-Recent-Company-Progress.html
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
Summer.76,
23.02.2022 15:32 Uhr
0
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
https://www.globenewswire.com/news-release/2022/02/23/2390327/0/en/Intellia-Therapeutics-Enters-Lease-Agreement-to-Build-Manufacturing-Facility-for-its-CRISPR-based-Therapies.html
• State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapies
• New facility in Waltham, Massachusetts expected to be operational in 2024
Summer.76,
15.02.2022 15:07 Uhr
0
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
https://finance.yahoo.com/news/intellia-onk-therapeutics-announce-collaboration-123000355.html
Summer.76,
03.02.2022 15:37 Uhr
0
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
https://www.globenewswire.com/news-release/2022/02/03/2378394/0/en/Intellia-Therapeutics-Announces-Acquisition-of-Rewrite-Therapeutics.html
d
donnralfo,
12.01.2022 22:18 Uhr
0
So langsam wird's wieder interessant. Ein Boden erkennt man nicht...
Summer.76,
31.12.2021 20:46 Uhr
0
https://www.nasdaq.com/articles/intellias-ntla-crispr-therapies-show-promise-amid-competition
Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition
Summer.76,
30.12.2021 19:46 Uhr
0
Ja, das Problem mit der Bewertung findet sich nicht nur hier und deshalb hatte ich nach der Durchbruchsmeldung auch meinen Bestand teils reduziert. Investiert bin ich weiterhin, aber von gerechtfertigt lässt sich natürlich nicht unbedingt sprechen 🙃. Eher davon, dass die Zukunft gehandelt wird.
J
JOEVBLACK,
30.12.2021 17:58 Uhr
0
Summer76, Du scheinst der Firma im Derail zu folgen. Ich überlege einnen Einstieg, finde aber die Bewertung ziemlich astronomisch. Ist sie gerexhtfertigt im Vergleich zu anderen Crispr-cas9 companies ?
Summer.76,
22.11.2021 14:54 Uhr
0
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
https://www.globenewswire.com/news-release/2021/11/22/2338871/0/en/Intellia-Therapeutics-Announces-Expansion-of-Ongoing-Phase-1-Study-of-NTLA-2001-to-Include-Adults-with-Transthyretin-Amyloidosis-with-Cardiomyopathy-ATTR-CM.html
Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy
B
BobbyBobberson,
04.11.2021 13:02 Uhr
0
Intellia accelerates plans to evaluate ATTR amyloidosis candidate in cardiomyopathy
Nov. 04, 2021 7:59 AM ETIntellia Therapeutics, Inc. (NTLA)By: Jonathan M Block, SA News Editor

Meletios Verras/iStock via Getty Images
Intellia Therapeutics (NASDAQ:NTLA) has decided to accelerate plans to evaluate NTLA-2001, its candidate for ATTR amyloidosis, in patients with cardiomyopathy.
The company said that based on an interim dataset, it is seeking regulatory feedback on inclusion of cardiomyopathy patients in its current phase 1 study.
Intellia is eyeing presenting interim data from part 1, a single-ascending dose portion, and to begin part 2, a single-cohort expansion, in Q1 2022.
Elsewhere in the pipeline, the company is planning to begin enrollment in a phase 1 study of NTLA-2002 for hereditary angioedema by the end of the year.
Also, by 1H 2022, Intellia's plans to nominate its first allogeneic development candidate.
In Q3 2021, Intellia's net loss widened ~158% to $71.6M (0.97 per share basic and diluted) due to a significant decline in collaboration revenue and an increase in R&D expenses
B
BobbyBobberson,
04.11.2021 12:49 Uhr
0
Ist natürlich noch nicht wirklich relevant
B
BobbyBobberson,
04.11.2021 12:49 Uhr
0
Intellia Therapeutics EPS misses by $0.11, misses on revenue
Nov. 04, 2021 7:32 AM ETIntellia Therapeutics, Inc. (NTLA)By: Gaurav Batavia, SA News Editor
Intellia Therapeutics (NASDAQ:NTLA): Q3 GAAP EPS of -$0.97 misses by $0.11.
Revenue of $7.21M (-67.5% Y/Y) misses by $1.45M.
Press Release
Cash, cash equivalents and marketable securities were $1,148.7 million as of September 30, 2021, compared to $597.4 million as of December 31, 2020. The increase was driven by net proceeds of $648.3 million from a follow-on offering in Q3 2021, $45.3 million of net proceeds from the Company’s “At the Market” agreement, $40.8 million in proceeds from employee-based stock plans, and $4.2 million of funding for a cost-sharing agreement received from Regeneron. These increases were offset in part by cash used to fund operations of approximately $187.3 million.
Summer.76,
21.10.2021 13:58 Uhr
1
Etwas ausführlicher:
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
https://www.globenewswire.com/news-release/2021/10/21/2318228/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2001-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis.html
Summer.76,
20.10.2021 18:28 Uhr
0
Intellia granted Orphan Drug designation for transthyretin amyloidosis program
https://newsfilter.io/a/a34daaacd54413360e2cadfaf0fcfc76
• The FDA has granted Orphan Drug designation to Intellia Therapeutics' (NTLA +0.3%) NTLA-2001 treatment for transthyretin amyloidosis ("ATTR").
• The gene editing therapy use a knockout edit to reduce circulating TTR protein levels.
• Intellia is partnered with Regeneron Pharmaceuticals (REGN +0.9%) on NTLA-2001.
• NTLA-2001 was granted Orphan Drug designation by the European Commission in March.
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Phunware ab 27.02.24 RS | -11,88 % | |
2 | für alle, die es ehrlich meinen beim Traden. | ||
3 | RENK (für normale, sachliche Kommunikation!) | +3,49 % | |
4 | NVIDIA Hauptdiskussion | +1,22 % | |
5 | VALNEVA SE Hauptdiskussion | -2,06 % | |
6 | EVOTEC Hauptdiskussion | +12,45 % | |
7 | Nio für normale Kommunikation | +5,00 % | |
8 | Phunware Hauptdiskussion | -11,88 % | |
9 | MicroStrategy | +1,68 % | |
10 | Super Micro Computer Hauptdiskussion | +8,35 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | Phunware ab 27.02.24 RS | -11,88 % | |
2 | RENK (für normale, sachliche Kommunikation!) | +3,30 % | |
3 | NVIDIA Hauptdiskussion | +1,22 % | |
4 | VALNEVA SE Hauptdiskussion | -2,33 % | |
5 | EVOTEC Hauptdiskussion | +12,45 % | |
6 | Nio für normale Kommunikation | +5,00 % | |
7 | Phunware Hauptdiskussion | -11,88 % | |
8 | MicroStrategy | +1,68 % | |
9 | TESLA MOTORS Hauptdiskussion | +3,19 % | |
10 | Super Micro Computer Hauptdiskussion | +9,38 % | Alle Diskussionen |